If you need help accessing our website, call 855-698-9991
Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.

Cristian C. Papazoglu Statescu, MD, PhD

Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.
  • Specialty: Hematology
  • Treats: Adults
  • Language: English

Conditions and Treatments

Conditions
  • acute myelogenous leukemia
  • aids-related malignancies
  • anemia
  • bladder cancer
  • central nervous system lymphoma
  • chronic myelogenous leukemia (cml)
  • cutaneous t-cell lymphoma
  • diffuse large b-cell lymphoma
  • essential thrombocythemia (et)
  • female germ cell tumor
  • hodgkin lymphoma
  • kidney cancer
  • male germ cell tumor
  • multiple myeloma
  • myelodysplastic syndromes (mds)
  • myelofibrosis
  • myeloproliferative disorder
  • non-hodgkin lymphoma
  • polycythemia vera
  • prostate cancer
  • sickle cell anemia
  • testicular cancer
  • thrombocytopenia
  • thrombosis
  • ureter cancer

Positions
Board Certifications
  • American Board of Internal Medicine (Medical Oncology), 2020
  • American Board of Internal Medicine (Hematology), 2019
  • American Board of Internal Medicine - Internal Medicine, 2017
Education and Training
  • Fellowship, Montefiore Medical Center/Albert Einstein College of Medicine, Hematology & Medical Oncology, 2019
  • Residency, Montefiore Medical Center/Albert Einstein College of Medicine, Internal Medicine, 2016
  • PhD from SUNY - Stony Brook, 2008
  • MD from Carol Davila University, 2003

Is this your profile?

Edit profile

Please call the office for information about accepted insurance plans.

Cristian C. Papazoglu Statescu, MD, PhD does not accept insurance.

Academic office

462 First Avenue, OBV-C&D Building

5th Floor, 556

New York, NY 10016

Phone

212-562-1135

Fax

212-263-8210

  • A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

    Learn More
  • A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

    Learn More
  • EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence

    Learn More
View All Research Studies (6)

Read All Publications (8)